Lansoprazol Krka (Lansoprazole)

Lansoprazole is indicated for acid‑related disorders that involve excessive gastric secretion.

• Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation.
• Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence.
• Helicobacter pylori eradication regimens: used as part of combination therapy to increase eradication success.

• Lansoprazole irreversibly binds to the H+/K+ ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By inhibiting this final step of acid secretion, it markedly lowers both basal and stimulated gastric acidity, creating a less hostile environment for ulcer healing and symptom control in reflux disease.

Lansoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: loose stools occurring during treatment.
• Nausea: feeling of stomach upset.
• Abdominal pain: discomfort in the upper abdomen.
• Flatulence: increased gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or breathing difficulty.
• Clostridioides difficile infection: persistent diarrhea with fever.
• Low magnesium levels: muscle cramps, irregular heartbeat.
• Bone fractures: increased risk with long‑term use.
• Liver enzyme elevation: abnormal liver function tests.

Before prescribing Lansoprazol Krka, consider the following safety measures.

• Assess renal function: dose adjustment may be needed in severe impairment.
• Review hepatic status: monitor for liver enzyme changes.
• Evaluate long‑term use: consider risk of fractures and vitamin B12 deficiency.
• Check for concomitant medications that affect gastric pH.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Lansoprazole can alter the absorption or metabolism of several drugs.

Major Interactions (Avoid)

• Antiretroviral protease inhibitors (e.g., atazanavir): reduced efficacy.
• Antifungal agents (e.g., ketoconazole, itraconazole): decreased absorption.
• Clopidogrel: reduced antiplatelet effect.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, monitor coagulation.
• Methotrexate: higher serum levels, watch for toxicity.
• Digoxin: altered absorption, check serum concentrations.